Cancers, Vol. 12, Pages 802: ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
Cancers, Vol. 12, Pages 802: ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
Cancers doi: 10.3390/cancers12040802
Authors:
Sieuwerts
Inda
Smid
van Ooijen
van de Stolpe
Martens
Verhaegh
: Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel testing method was reported before that enables measurement of functional signal transduction pathway activity in individual cancer tissue samples, using mRNA levels of target genes of the respective pathway-specific transcription factor. Using this method, 130 primary breast cancer samples were analyzed from non-metastatic ER+ patients, treated with surgery without adjuvant hormonal therapy, who subsequently developed metastatic disease that was treated with first-line tamoxifen. Quantitative activity levels were measured of androgen and estrogen receptor (AR and ER), PI3K-FOXO, Hedgehog (HH), NFκB, TGFβ, and Wnt pathways. Based on samples with known pathway activity, thresholds were set to distinguish low from high activity. Subsequently, pathway activity levels were correlated with the tamoxifen treatment response and progression-f...
Source: Cancers - Category: Cancer & Oncology Authors: Sieuwerts Inda Smid van Ooijen van de Stolpe Martens Verhaegh Tags: Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Genetics | Hormonal Therapy | Hormones | Tamoxifen